Tech Company Financing Transactions
Avaxia Biologics Funding Round
Avaxia Biologics, based in Lexington, secured $1 million from private investors.
Transaction Overview
Company Name
Announced On
7/21/2015
Transaction Type
Debt
Venture Equity
Venture Equity
Amount
$1,005,777
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed. SEC regulatory filing. Contact technology company for investment details, if applicable. Not an offer or solicitation for sale of securities.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
128 Spring St. 620
Lexington, MA 02421
USA
Lexington, MA 02421
USA
Phone
Website
Email Address
Overview
Avaxia Biologics develops orally-delivered antibody therapeutics using a proprietary antibody platform.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Barbara Fox
Chief Financial Officer
David Neafus
VP - Operations
Neil Schauer
Browse more venture capital transactions:
Prev: 7/20/2015: Protagonist Therapeutics venture capital transaction
Next: 7/21/2015: Bidtellect venture capital transaction
Share this article
About Our VC Transactions Data
We record every notable VC transaction. All VC database entries on this site are derived from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs